Is Boston Scientific Still The Business You Bought?
For questions about this article or underlying research, email help@trefis.com.
If you own Boston Scientific (BSX) stock, you likely bought a fast-growing device maker. Management said on its October 28, 2026 call that the company had enjoyed several years of exceptional growth. The company lowered its outlook that day. Over the twelve months to November 13, 2026, the shares lost 57.4%, while the S&P 500 returned 11.7%. So is Boston Scientific still the company you paid for, or has something more lasting changed?

Partly: Boston Scientific Earns More But Keeps Less Cash
Boston Scientific still makes more profit on each dollar of sales than it used to. Over the twelve months to September 30, 2026, its operating margin was 20.6%, up from 19.2% a year earlier. This margin sits well above the 15.7% median of its quarter ends from the end of 2012 to September 2025.
At the same time, the company has put far more of its cash back into the business. Over the same twelve months, capital spending took 12.9% of revenue, against a median of 5.0% from the end of 2012 to September 2025. That spending came to $2.72 billion, or 64.2% of the cash the business brought in from operations. Much of it landed in the quarter to June 30, 2026, when free cash flow was negative $0.451 billion. The cash left over after spending fell to $1.52 billion over the twelve months, down from $3.57 billion a year earlier.
Boston Scientific Lost Growth To Rivals And A Cyberattack
The underlying business has changed too. Revenue grew 1.4% in the quarter to September 30, 2026, against 20.3% growth in the same quarter a year before. Management estimates that a cyber incident, which left the company unable to manufacture or ship product for eight business days, took about 3 percentage points off that growth.
The longer problem sits in two franchises. WATCHMAN sales fell 7% in the U.S., and sales in the business built on the FARAPULSE platform fell 5% worldwide and 8% in the U.S., as management says its market share has eroded to newer technologies. Management also pointed to tougher pricing in China, while the rest of the company, about 75% of it, is still growing. Management expects 2027 to be the low point of this cycle and aims to return to high performance in 2028.
What Boston Scientific’s Shift Means For Your Money
Boston Scientific paid no dividends over the twelve months to September 30, 2026. At the end of that quarter it held $0.609 billion in cash against $12.0 billion of debt, though debt was 26.3% of assets, below its 29.8% median from the end of 2012 to September 2025.
Boston Scientific also expects to close its purchase of Penumbra in early 2027. Management has said higher interest rates will add to the dilution of earnings per share it expected from that deal.
Before, you could count on fast growth and plenty of cash left over each year. Neither holds as strongly today, though profit per dollar of sales is above its long-run median. For the risk to be worth taking, the heavier spending and the coming deal have to turn back into growth. Whether sales grow faster than capital spending is the measure to watch when Boston Scientific reports again, expected in February 2027.
Want Income That Doesn’t Hang On One Company?
Every single stock carries risks like these. The Trefis Income Solution spreads your money across 50 dividend stocks, each with at least 10 straight years of dividends, with a yield about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.